Bioengineered Protein Drug Market Size & Share, by Drug Type (Recombinant Protein, Vaccine, Peptide Antibiotics, Therapeutic Enzymes); Application (Autoimmune, Heart, Congenital, Infectious Diseases, Cancer, Diabetes, Arthritis); Technology (Genetic Engineering, Cell Culture, Pharming); Drug Delivery Method (Traditional Methods, Novel Approaches) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2023-2035

  • Report ID: 2828
  • Published Date: Mar 16, 2023
  • Report Format: PDF, PPT

Companies Dominating the Bioengineered Protein Drug Landscape

top-features-companies
    • Abbott Services
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Johnson & Johnson Services, Inc.
    • Amgen Inc.
    • Bayer AG
    • Dr. Reddy’s Laboratories Ltd.
    • Biocon Limited
    • Eli Lilly and Company
    • Sanofi S.A
    • GlaxoSmithKline plc
    • F. Hoffmann-La Roche Ltd

Browse Key Market Insights with Data Illustration:

In-the-news

In The News

  • Abbott acquired St. Jude Medical, Inc., a medical device firm. The acquisition is expected to help Abbott Laboratories expand its market share in medical devices and improve its bio-engineered stent product range worldwide.

  • GlaxoSmithKline plc announced the retrospective study results on clinical trial diversity. The study included 495 GSK and ViiV clinical trials and was based on US participants.


Author Credits:  Radhika Gupta, Shivam Bhutani


  • Report ID: 2828
  • Published Date: Mar 16, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

Growing prevalence of cancer and growing incidences of diabetes are the major factors driving the market growth.

The market is anticipated to attain a CAGR of 5% over the forecast period, i.e., 2023-2035.

The higher possibility of the unwanted immune response against themselves and membrane impermeability and poor In Vivo stability are estimated to be the growth hindering factors for the market expansion.

The market in the North American region is projected to hold the largest market share by the end of 2035 and provide more business opportunities in the future.

The major players in the market are Johnson & Johnson Services, Inc., Amgen Inc., Bayer AG, Dr. Reddy’s Laboratories Ltd., Biocon Limited, Eli Lilly and Company, Sanofi S.A, GlaxoSmithKline plc, and others.

The company profiles are selected based on the revenues generated from the product segment, the geographical presence of the company which determines the revenue generating capacity as well as the new products being launched into the market by the company.

The market is segmented by drug type, application, technology, drug delivery method, and by region.

The therapeutic enzymes segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.
Inquiry Before Buying Request Free Sample
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying